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Summary
Background Rare cancers pose challenges for diagnosis, treatments, and clinical decision making. Information about rare 
cancers is scant. The RARECARE project defined rare cancers as those with an annual incidence of less than six per 
100 000 people in European Union (EU). We updated the estimates of the burden of rare cancers in Europe, their time 
trends in incidence and survival, and provide information about centralisation of treatments in seven European countries.
Methods We analysed data from 94 cancer registries for more than 2 million rare cancer diagnoses, to estimate 
European incidence and survival in 2000–07 and the corresponding time trends during 1995–2007. Incidence was 
calculated as the number of new cases divided by the corresponding total person-years in the population. 5-year 
relative survival was calculated by the Ederer-2 method. Seven registries (Belgium, Bulgaria, Finland, Ireland, the 
Netherlands, Slovenia, and the Navarra region in Spain) provided additional data for hospitals treating about 
220 000 cases diagnosed in 2000–07. We also calculated hospital volume admission as the number of treatments 
provided by each hospital rare cancer group sharing the same referral pattern.
Findings Rare cancers accounted for 24% of all cancers diagnosed in the EU during 2000–07. The overall incidence 
rose annually by 0.5% (99·8% CI 0·3–0·8). 5-year relative survival for all rare cancers was 48·5% (95% CI 48·4 to 48·6), 
compared with 63·4% (95% CI 63·3 to 63·4) for all common cancers. 5-year relative survival increased (overall 2·9%, 
95% CI 2·7 to 3·2), from 1999–2001 to 2007–09, and for most rare cancers, with the largest increases for haematological 
tumours and sarcomas. The amount of centralisation of rare cancer treatment varied widely between cancers and 
between countries. The Netherlands and Slovenia had the highest treatment volumes.
Interpretation Our study benefits from the largest pool of population-based registries to estimate incidence and 
survival of about 200 rare cancers. Incidence trends can be explained by changes in known risk factors, improved 
diagnosis, and registration problems. Survival could be improved by early diagnosis, new treatments, and improved 
case management. The centralisation of treatment could be improved in the seven European countries we studied.
Funding The European Commission (Chafea).
Introduction
The RARECARE project1 defined rare cancers as those 
with an annual incidence of less than six per 100 000 
people in the European Union (EU), and showed that 
about one in five cancers diagnosed in the EU were rare 
and slightly more than 4 million people with a rare 
cancer diagnosis were living in the EU population. 
Because of their low numbers, the almost 200 rare 
cancers listed by RARECARE pose challenges for 
diagnosis, treatments, and clinical decision making. 
Clinical trials into such cancers are rare too, and it is 
hard to build up new knowledge and expertise.
The broad consensus suggests that diagnostic 
pathological confirmation and primary treatment of rare 
cancers, in particular, should be centralised in reference 
centres, collaborative networks, or both, with multi­
disciplinary approaches2 and very specific expertise. 
Additionally, clinical and translational research calls for a 
high level of centralisation and international collaboration. 
To what extent appropriate policies for patients with rare 
cancer are implemented at the country level has seldom 
been studied. As a consequence, information for policy 
makers and stakeholders is scarce for many of these rare 
tumours.
The project Information Network on Rare Cancers 
(RARECAREnet) is designed to update epidemiological 
information about rare cancers in the EU,3 to provide 
indicators at the country level, time trends, and to study 
to what extent treatment is centralised in Europe.
In this study, we provide current incidence and survival 
estimates based on data collected from 94 population­
based cancer registries, for 198 rare cancers diagnosed in 
2000–07 and for 12 major families of rare cancers. We also 
present data for the levels of centralisation for rare cancers 
in selected European countries.
Methods
Patients
We extracted data from two databases. The first, the 
descriptive analysis database, is a subset of the 
EUROCARE­5 database,4 which includes incidence and 
follow­up data provided by European population­based 
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cancer registries for patients with cancer diagnosed 
between Jan 1, 1978, and Dec 31, 2007. Vital status was 
updated to Dec 31, 2008. From the 117 cancer registries 
participating in EUROCARE­5, we excluded specialised 
paediatric cancer registries, the Swedish and Turin 
cancer registries, because they did not participate in the 
RARECAREnet study, and the Danish cancer registry, 
because it did not provide the morphology detail needed 
to define rare cancers. Details of the RARECAREnet 
database can be found in the report on the project 
website.5 To analyse incidence, we excluded 11 anatomical­
site­specific cancer registries to avoid incomplete 
coverage of some cancer entities affecting multiple sites 
such as neuroendocrine tumours. We excluded cases 
identified only by death certificate or incidentally 
discovered at autopsy from the analysis because they do 
not report time of survival. Cases lost to follow­up were 
considered as censored at the date of last contact. 
We included multiple primaries in the same patient. 
The second database was used for the study of hospitals 
of treatment and hospital volume, which includes data 
from seven European cancer registries: the national 
cancer registries of Belgium, Bulgaria, Finland, Ireland, 
the Netherlands, Slovenia, and the regional cancer 
Research in context
Evidence before the study
The surveillance of rare cancer in Europe (RARECARE) project 
provided data from European population-based cancer registries 
to provide for the first time the burden of rare cancers in Europe. 
The RARECARE definition of rare cancer was an incidence of less 
than six cases per 100 000 people per year. A list of rare cancers 
was created, combining the topography and morphology codes 
from the International Classification of Diseases for Oncology 
(ICD-O-3). The list was produced after consultations by a group 
of pathologists, clinicians and epidemiologists, and was 
endorsed by the main European cancer organisations. The 
definition and the list were employed in several European and 
extra-European countries. The European Commission (EC) based 
the recent launch of the Joint Action on Rare Cancer in line with 
this definition. Estimates indicated that about one in five new 
cancers were rare and slightly more than 4 million people 
diagnosed with rare cancers lived in Europe. Outcomes (5-year 
relative survival) were worse for patients with rare cancers than 
for patients with common cancers.
There is general agreement that treatment of rare cancers should 
be concentrated in specialised multidisciplinary centres, and that 
international collaboration is needed for research on these 
cancers. However, there is no knowledge about the extent of 
centralisation of rare cancer treatment at the population level.
Added value of this study
With the new project ‘Information network on rare cancer’ 
(RARECAREnet), we updated the burden of rare cancer and 
provided indicators of the centralisation of patients with rare 
cancer in seven European countries. We estimated about 
650 000 new diagnoses of rare cancers occur yearly in Europe, 
with an incidence of 115 of 100 000 per year. The incidence rose 
by 0·5% annually, due to overdiagnosis (eg, thyroid carcinoma) 
or improved diagnosis (eg, neuroendocrine tumours [NET], 
gastrointestinal stromal tumour [GIST]) or increases in 
exposure to risk factors (such as HPV). 5-year survival for rare 
cancers (49%) is still lower than for common cancers (63%), but 
has risen, from 46% in 1999–2001 to 49% in 2005–07. 
Significant progress was reported for some poor-prognosis 
cancers, such as chronic myeloid leukaemia, 
gastroenteropancreatic tumours (GEP), soft tissue sarcoma of 
viscera, plasmocytoma or multiple myeloma, and oesophageal 
cancers. Seven European countries provided data to study the 
extent of hospital centralisation for rare cancers and these data 
showed that, overall, centralisation of rare cancer treatment 
varied widely between countries and was generally low.
Implication of all the evidence
Rare cancers are a specific group of rare diseases requiring, 
compared with other rare diseases, the largest expenditure for 
drugs. The rare disease community has strongly lobbied the EC 
to increase investment in research, management, and social 
support for these diseases. This very large population-based 
study on rare cancers thus provides useful information for 
public health. The EC recognised the results of RARECARE and 
RARECAREnet and launched a European Joint Action for Rare 
Cancers in 2016 aiming to help member states with their 
national health plans. The EC also recently approved 
two specific rare cancer European Reference Networks (ERN), 
for childhood and solid cancers, to exchange management of 
very rare cancers or to treat patients from small countries. Both 
initiatives can use these data, with national and European 
health-care institutions, to address the issue of rare cancers 
better.
Lower survival of patients with rare cancer might be explained 
by difficulties in clinical research, as well as their specific 
biological characteristics, and our results have shown that  
non-optimal organisation of care can have a role too. There is 
ample room for improving the levels of centralisation of 
treatment and clinical expertise in seven European countries. 
These results were discussed in national meetings, and 
confirmed the need for improving the centralisation of rare 
cancer treatment in fewer, more specialised hospitals. Our data 
offer a starting point to measure the effects of new policies on 
rare cancers.
Data provided by cancer registries are essential, but their quality 
has to improve, especially on morphology, hospital and treatment 
definitions. Basic information on stage and the determinants of 
stage needs to be collected routinely. The European network of 
cancer registries should work to boost these improvements and 
make wider use of the data on rare cancers.
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registry of Navarra (Spain). The Navarra cancer registry, 
although regional, was added because of the regional 
organisation of the Spanish health­care system. These 
cancer registries were selected to reflect the variability of 
incidence and survival in Europe,1,5 and because they 
could provide detailed data for all 198 rare cancers 
included in the RARECAREnet list. Variables included in 
the database were: sex, date of birth, date of diagnosis, 
topography and morphology codes from the International 
Classification of Disease for Oncology version 3 (ICDO­3) 
grading, pathological and clinical TNM Classification of 
Malignant Tumours (TNM) staging, simplified stage 
(localised, regional extension, metastatic), treatment 
(surgery, radiotherapy, systemic, other, or none), vital 
status, date of last follow­up or death, hospital of 
diagnosis, and hospital of treatment. The hospital of 
diagnosis was defined as the hospital where the pathology 
examination was done or requested. The hospital of 
treatment(s) was defined as the hospital where a specific 
treatment (eg, surgery) or the first course of systemic 
therapy (eg, chemotherapy) was given. Up to five different 
types of treatment within 1 year from the date of diagnosis 
were considered as a primary treatment. Vital status was 
further updated in this second database, with respect to 
the first descriptive analysis database, to Dec 31, 2012. 
Analysis
The rationale for the definition of rare cancer entities and 
their classification in terms of ICD­O codes are reported 
elsewhere.1,2,5 Classification was structured to avoid any 
overlap among rare entities. For example, gastro entero­
hepatic neuroendocrine tumours and gastro intestinal 
stromal tumours were under the families of neuro­
endocrine tumours and sarcomas, but not also in 
digestive rare cancers.
From the first database, we estimated incidence as the 
number of new cases arising in 2000–07 divided by the 
corresponding total person­years (male and female) in 
the general population. The European standard 
population was used for direct age standardisation. New 
cases in 2013 in EU28 (28 member states of EU) were 
calculated by multiplying age­specific and sex­specific 
incidence rates in 2000–07 by the corresponding 
European population classified in 5­year age classes on 
Jan 1, 2013.
We estimated incidence variation by restricting 
the analysis to cases diagnosed in the two sub­periods 
1999–2002 and 2003–07, and presented the results in a 
funnel plot. Annual percentage change was calculated as 
the ratio between incidence rates for the two sub­periods 
to the power of 1 over 4·5, the inverse of the mean 
difference in time between the two sub­periods.
We estimated 5­year relative survival as the ratio of 
observed to expected survival in the general population, 
matched by age, sex, calendar year, and geographical 
area, and calculated by the Ederer­2 method.6 
We estimated relative survival time trends using the 
period approach and considering three follow­up periods: 
1999–2001 (cohorts diagnosed in Jan 1, 1995, to 
Dec 31, 2001), 2002–04 (cohorts diagnosed in Jan 1,1998 to 
Dec 31, 2004), and 2005–07 (cohorts diagnosed in 
Jan 1, 2001, to Dec 31, 2007). We presented relative 
survival changes as a funnel plot.
The volume (number) of treatments provided by each 
hospital was calculated from the second database for 
major cancer groups, defined by aggregating all the solid 
rare cancers into 38 groups sharing the same referral 
pattern. For example, all seven head and neck tumours 
identified as clinically distinct rare entities1 are usually 
referred to head and neck specialised services, and we 
considered these as a single group. Haematological rare 
tumours do not always require hospitalisation and we 
did not consider these in the volume analysis. We then 
computed hospital volume for each of the 38 groups as 
the annual number of any treatment delivered by the 
hospital, for all the cancers in that group. We regarded 
repeated admissions to the same hospital for the same 
cancer and the same treatment type (ie, surgery, 
radiotherapy, or systemic therapy) as a single admission 
and counted as one treatment in the analyses. Repeated 
admissions for several treatment types (such as 
radiotherapy and subsequent surgery) given to a patient 
in the same hospital were counted as separate treatments. 
Untreated patients were assigned to the hospital of 
diagnosis. The total number of treatments provided by 
each hospital for a given group of rare cancers was then 
divided by the number of years of observation to provide 
its mean annual hospital volume. Pearson’s correlation 
coefficient was used to evaluate the association, across 
cancers, between mean admission volume and incidence.
Finally, for each patient we calculated the mean annual 
volume of the hospital(s) where they were treated to 
obtain a patient­specific measure with a much less 
skewed distribution with respect to the hospital­specific 
volume. The mean value of this measure for all the 
patients diagnosed with a given group of rare cancers in 
a certain country gives a cancer­specific and country­
specific measure of the level of expertise that patients can 
expect for the treatment of their tumour. We called this 
calculation the mean admission volume indicator.
Role of the funding source
The funders had no role in study design, collection, 
analysis or interpretation of data, or writing of the report. 
The corresponding author had full access to all the data 
and had final responsibility for the decision to submit for 
publication.
Results
Survival estimates in 2000–07 for all rare cancers were 
based on 1 994 346 diagnoses, observed by 94 cancer 
registries. 1 984 147 rare cancer diagnoses were considered 
for incidence estimates in 2000–07, collected by 83 cancer 
registries from 1566 million person­years of observation. 
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62 828 (3%) of 1 984 147 cases were identified by death 
certificate only or incidentally at autopsy ranging from a 
maximum of 4412 (10%) of 44 755 cases in Slovakia, to 
265 (<1%) of 60 377 cases in Scotland. Data for incidence 
time trends came from 42 cancer registries for 1995–2007, 
and included 2 268 602 cases, and 1900 million person­
years of observation. Survival time trend analysis was 
based on 1 649 309 rare cancer diagnoses from 45 cancer 
registries providing uninterrupted data from at least 
Jan 1, 1995, to Dec 31, 2007.
For the study of hospitals of treatment and hospital 
volume, we received data for about 348 000 rare cancers 
diagnosed in the period 2000–07. However, national data 
from Belgium were limited to 2004–07, and those from 
Navarra to 2000–05. Cases diagnosed in Bulgaria and the 
Netherlands during 2000–04 were removed on account of 
incomplete national coverage of hospital information. 
223 081 rare cancer cases were included in the hospital 
volume study database. Non­specific morphologies 
(8000, 8001, 8010, 8800, 9800, 9590) were found in 4588 
(2%), with the highest proportion in Finland (1268 [4%] 
of 30 740 cases). 37 959 (17%) of 223 081 cases were 
removed because hospital information was missing.
Table 1 shows the incidence and survival estimates for 
each of the 198 rare cancers, for 63 groups of rare 
cancers, for the 12 wider families in which rare cancers 
are hierarchically grouped, and for six common cancer 
groups. Haematological malignancies, rare cancers 
of female genital organs and of the digestive tract, 
and head and neck cancers were families with the 
highest overall incidence rates (from 19 to 28 
per 100 000 people per year). Thoracic cancers, male 
Crude incidence 
rate per 
100 000 people  
per year
95% CI Observed cases 
in 83 cancer 
registries in 
2000–07
Estimated 
new cases in 
2013 in EU28
5-year 
relative 
survival (%)
95% CI Observed cases 
in 94 cancer 
registries in 
2000–07
Rare: head and neck cancers 18·82 16·76–16·89 263 565 84 989 52·1% 51·8–52·3 254 563
Epithelial tumours of nasal cavity and sinuses 0·45 0·44–0·46 7046 2282 47·3% 45·8–48·8 6867
Squamous cell carcinoma with variants of nasal cavity and 
sinuses
0·35 0·34–0·36 5465 1770 49·5% 47·8–51·2 5444
Lymphoepithelial carcinoma of nasal cavity and sinuses 0·00 0·00–0·00 31 10 70·8% 50·7–99·0 31
Undifferentiated carcinoma of nasal cavity and sinuses 0·02 0·02–0·02 286 93 30·5% 24·3–38·2 283
Intestinal-type adenocarcinoma of nasal cavity and sinuses 0·00 0·00–0·00 42 14 65·0% 48·9–86·4 42
Epithelial tumours of nasopharynx 0·47 0·46–0·49 7439 2580 48·9% 47·5–50·2 7276
Squamous cell carcinoma with variants of nasopharynx 0·36 0·35–0·37 5613 1941 48·5% 47·0–50·1 5589
Papillary adenocarcinoma of nasopharynx 0·00 0·00–0·00 17 6 58·7% 36·2–95·3 17
Epithelial tumours of major salivary glands and salivary-gland-
type tumours
1·39 1·37–1·41 21 794 7059 62·8% 62·0–63·7 21 364
Epithelial tumours of major salivary glands 0·96 0·95–0·98 15 053 4876 60·8% 59·8–61·8 14 703
Salivary-gland-type tumours of head and neck 0·43 0·42–0·44 6741 2183 67·1% 65·7–68·6 6683
Epithelial tumours of hypopharynx and larynx 6·33 6·29–6·37 99 176 31 545 52·0% 51·6–52·4 96 793
Squamous cell carcinoma with variants of hypopharynx 1·27 1·25–1·28 19 828 6422 25·1% 24·4–25·9 19 878
Squamous cell carcinoma with variants of larynx 4·61 4·58–4·64 72 210 23 389 60·5% 60·1–61·0 71 928
Epithelial tumours of oropharynx 3·32 3·29–3·35 52 017 16 848 40·9% 40·4–41·4 50 843
Squamous cell carcinoma with variants of oropharynx 3·12 3·09–3·14 48 812 15 810 41·3% 40·8–41·8 48 401
Epithelial tumours of oral cavity and lip 4·78 4·75–4·81 74 890 24 257 56·7% 56·2–57·1 73 101
Squamous cell carcinoma with variants of oral cavity 3·51 3·48–3·54 54 931 17 792 48·0% 47·5–48·6 54 229
Squamous cell carcinoma with variants of lip 1·02 1·00–1·04 15 984 5177 89·5% 88·5–90·5 15 899
Epithelial tumours of eye and adnexa 0·04 0·04–0·05 679 247 80·6% 75·9–85·6 673
Squamous cell carcinoma with variants of eye and adnexa 0·03 0·02–0·03 421 136 88·9% 83·0–95·2 422
Adenocarcinoma with variants of eye and adnexa 0·01 0·01–0·01 134 43 58·7% 49·1–70·1 134
Epithelial tumours of middle ear 0·03 0·03–0·04 524 170 44·1% 38·5–49·6 488
Squamous cell carcinoma with variants of middle ear 0·02 0·02–0·03 377 122 37·6% 31·8–44·4 370
Adenocarcinoma with variants of middle ear 0·00 0·00–0·00 50 16 83·8% 70·5–99·5 50
Rare: digestive cancers 21·94 21·86–22·01 343 635 112 351 15·3% 15·2–15·5 321 375
Epithelial tumours of oesophagus 7·81 7·77–7·85 122 344 40 068 12·0% 11·8–12·2 119 522
Squamous cell carcinoma with variants of oesophagus 3·36 3·33–3·39 52 597 17 036 11·7% 11·3–12·0 53 225
Adenocarcinoma with variants of oesophagus 3·26 3·24–3·29 51 138 16 564 13·9% 13·5–14·2 51 250
Salivary-gland-type tumours of oesophagus 0·00 0·00–0·01 63 20 13·7% 6·4–29·0 64
Undifferentiated carcinoma of oesophagus 0·04 0·04–0·05 695 225 6·8% 4·9–9·4 712
(Table 1 continues on next page)
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Crude incidence 
rate per 
100 000 people 
per year
95% CI Observed cases 
in 83 cancer 
registries in 
2000–07
Estimated 
new cases in 
2013 in EU28
5-year 
relative 
survival (%)
95% CI Observed cases 
in 94 cancer 
registries in 
2000–07
(Continued from previous page)
Rare epithelial tumours of stomach 0·33 0·32–0·34 5146 1886 15·9% 14·7–17·1 5157
Squamous cell carcinoma with variants of stomach 0·12 0·11–0·12 1807 585 17·5% 15·6–19·7 1800
Salivary-gland-type tumours of stomach 0·00 0·00–0·00 39 13 25·1% 12·7–49·9 40
Undifferentiated carcinoma of stomach 0·21 0·20–0·22 3300 1069 14·9% 13·5–16·4 3317
Epithelial tumours of small intestine 0·77 0·76–0·79 12 132 3930 27·3% 26·3–28·3 11 544
Adenocarcinoma with variants of small intestine 0·59 0·58–0·60 9219 2986 27·9% 26·8–29·0 9193
Squamous cell carcinoma with variants of small intestine 0·01 0·01–0·01 133 43 34·8% 26·8–45·3 133
Rare epithelial tumour of colon 0·13 0·13–0·14 2074 737 54·8% 52·0–57·7 2075
Squamous cell carcinoma with variants of colon 0·03 0·02–0·03 400 130 37·1% 31·8–43·4 395
Fibromixoma and low-grade mucinous adenocarcinoma of the 
appendix
0·11 0·10–0·11 1674 542 58·8% 55·7–62·1 1680
Rare epithelial tumours of rectum 0·11 0·11–0·12 1764 635 47·2% 44·4–50·2 1777
Squamous cell carcinoma with variants of rectum 0·11 0·11–0·12 1764 571 47·2% 44·4–50·2 1777
Epithelial tumours of anal canal 1·16 1·14–1·18 18 155 5880 56·5% 55·5–57·4 18 020
Squamous cell carcinoma with variants of anal canal 0·81 0·80–0·82 12 691 4111 63·0% 61·9–64·1 12 847
Adenocarcinoma with variants of anal canal 0·25 0·25–0·26 3970 1286 41·9% 39·9–43·9 3945
Paget’s disease of anal canal 0·00 0·00–0·00 21 7 62·9% 38·0–104·0 21
Rare epithelial tumours of pancreas 0·07 0·07–0·08 1159 414 20·2% 17·4–23·3 1116
Squamous cell carcinoma with variants of pancreas 0·02 0·02–0·03 361 117 5·9% 3·6–9·6 347
Acinar cell carcinoma of pancreas 0·03 0·03–0·03 449 145 19·0% 14·8–24·3 427
Mucinous cystadenocarcinoma of pancreas 0·01 0·01–0·01 109 35 35·9% 26·3–49·0 106
Intraductal papillary mucinous carcinoma invasive of pancreas 0·01 0·01–0·01 173 56 31·8% 23·6–42·9 171
Solid pseudopapillary carcinoma of pancreas 0·00 0·00–0·00 44 14 67·7% 52·8–86·8 42
Serous cystadenocarcinoma of pancreas 0·00 0·00–0·00 4 1 NE NE 4
Carcinoma with osteoclast-like giant cells of pancreas 0·00 0·00–0·00 19 6 NE NE 19
Epithelial tumours of liver and intrahepatic bile tract 7·10 7·06–7·14 111 271 36 261 10·1% 9·9–10·3 98 765
Hepatocellular carcinoma of liver and intrahepatic bile tract 3·22 3·19–3·25 50 461 16 344 14·0% 13·7–14·4 46 896
Hepatocellular carcinoma, fibrolamellar of liver and 
intrahepatic bile tract
0·02 0·02–0·03 387 125 28·1% 23·3–33·8 390
Cholangiocarcinoma of intrahepatic bile tract 0·97 0·95–0·99 15 201 4924 6·0% 5·6–6·6 13 845
Adenocarcinoma with variants of liver and intrahepatic bile 
tract
0·41 0·40–0·42 6457 2091 6·6% 5·9–7·4 6311
Undifferentiated carcinoma of liver and intrahepatic bile tract 0·02 0·01–0·02 240 78 2·7% 1·2–6·4 219
Squamous cell carcinoma with variants of liver and 
intrahepatic bile tract
0·01 0·01–0·01 147 48 14·6% 9·1–23·4 143
Bile duct cystadenocarcinoma of intrahepatic bile tract 0·00 0·00–0·00 38 12 23·6% 11·5–48·5 34
Epithelial tumours of gallbladder and extrahepatic biliary tract 4·44 4·41–4·48 69 590 22 540 13·6% 13·2–13·9 63 889
Adenocarcinoma with variants of gallbladder 1·35 1·33–1·36 21 085 6830 14·5% 14·0–15·1 20 338
Adenocarcinoma with variants of extrahepatic biliary tract 1·44 1·42–1·46 22 510 7291 19·2% 18·6–19·8 22 234
Squamous cell carcinoma of gallbladder and extrahepatic 
biliary tract
0·03 0·03–0·03 496 161 8·8% 6·3–12·3 476
Rare: thoracic cancers 6·80 6·76–6·84 106 573 37 277 13·4% 13·1–13·6 104 670
Epithelial tumour of trachea 0·11 0·11–0·12 1771 574 18·0% 16·0–20·3 1697
Squamous cell carcinoma with variants of trachea 0·06 0·06–0·07 1017 329 12·2% 10·0–14·9 1008
Adenocarcinoma with variants of trachea 0·01 0·01–0·01 164 53 15·7% 10·3–24·0 158
Salivary-gland-type tumours of trachea 0·01 0·01–0·01 175 57 70·1% 62·0–79·2 174
Rare epithelial tumour of lung 4·37 4·34–4·40 68 452 24 930 14·9% 14·6–15·2 67 936
Adenosquamous carcinoma of lung 0·29 0·29–0·30 4607 1492 21·9% 20·5–23·4 4566
Large-cell carcinoma of lung 3·81 3·78–3·84 59 714 19 342 13·9% 13·5–14·2 59 332
Salivary-gland-type tumours of lung 0·06 0·05–0·06 879 285 40·4% 36·8–44·4 866
Sarcomatoid carcinoma of lung 0·21 0·20–0·22 3255 1054 17·5% 16·0–19·2 3183
(Table 1 continues on next page)
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Epithelial tumours of thymus 0·18 0·17–0·19 2795 905 64·3% 62·1–66·6 2729
Malignant thymoma 0·14 0·14–0·15 2268 735 69·3% 67·0–71·8 2248
Squamous cell carcinoma of thymus 0·01 0·01–0·01 114 37 40·4% 30·4–53·7 112
Undifferentiated carcinoma of thymus 0·00 0·00–0·00 36 12 13·3% 5·1–34·8 36
Lymphoepithelial carcinoma of thymus 0·00 0·00–0·00 12 4 55·0% 29·2–103·6 11
Adenocarcinoma with variants of thymus 0·00 0·00–0·00 45 15 37·3% 21·7–64·1 44
Malignant mesothelioma 2·14 2·12–2·16 33 552 10 868 5·3% 4·9–5·6 32 330
Mesothelioma of pleura and pericardium 1·83 1·81–1·85 28 676 9288 4·6% 4·2–4·9 27 893
Mesothelioma of peritoneum and tunica vaginalis 0·13 0·13–0·14 2065 669 13·2% 11·5–15·1 1965
Rare: female genital cancers 22·73 22·66–22·81 356 151 113 796 57·7% 57·5–57·9 347 015
Rare epithelial tumours of breast 4·12 4·09–4·16 64 605 22 980 91·4% 91·0–91·8 64 368
Mammary Paget’s disease of breast 0·41 0·40–0·42 6488 2101 85·9% 84·6–87·3 6508
Special types of adenocarcinoma of breast 3·06 3·04–3·09 48 012 15 551 95·2% 94·8–95·6 47 974
Metaplastic carcinoma of breast 0·10 0·10–0·11 1576 510 65·0% 61·9–68·3 1583
Salivary-gland-type tumours of breast 0·06 0·05–0·06 868 281 90·9% 87·6–94·2 870
Epithelial tumour of male breast 0·52 0·51–0·53 8098 5376 77·0% 75·5–78·5 7882
Rare epithelial tumours of corpus uteri 0·70 0·69–0·72 11 038 3932 44·3% 43·2–45·5 11 013
Squamous cell carcinoma with variants of corpus uteri 0·06 0·06–0·07 1003 325 58·2% 54·6–62·1 989
Adenoid cystic carcinoma of corpus uteri 0·00 0·00–0·00 5 2 64·1% 31·3–131·1 5
Clear cell adenocarcinoma, not otherwise specified of corpus 
uteri
0·16 0·16–0·17 2527 819 58·6% 56·2–61·2 2532
Serous (papillary) carcinoma of corpus uteri 0·08 0·07–0·08 1227 397 40·0% 36·5–43·9 1225
Mullerian mixed tumour of corpus uteri 0·40 0·39–0·41 6276 2033 36·9% 35·5–38·4 6263
Epithelial tumours of cervix uteri 6·28 6·24–6·32 98 321 28 898 65·4% 65·1–65·8 96 821
Squamous cell carcinoma with variants of cervix uteri 4·73 4·70–4·76 74 105 24 003 66·8% 66·5–67·2 73 810
Adenocarcinoma with variants of cervix uteri 0·91 0·89–0·92 14 252 4616 67·4% 66·5–68·3 14 221
Undifferentiated carcinoma of cervix uteri 0·03 0·03–0·03 480 155 35·3% 30·9–40·4 478
Mullerian mixed tumour of cervix uteri 0·02 0·01–0·02 257 83 34·3% 28·1–41·7 256
Epithelial tumour of ovary and fallopian tube 9·38 9·33–9·43 146 908 45 382 37·5% 37·2–37·8 141 240
Adenocarcinoma with variants of ovary 5·95 5·92–5·99 93 263 30 208 38·7% 38·3–39·1 92 814
Mucinous adenocarcinoma of ovary 0·77 0·76–0·78 12 066 3908 59·9% 58·9–60·9 12 010
Clear cell adenocarcinoma of ovary 0·30 0·29–0·31 4753 1540 55·5% 53·8–57·2 4761
Primary peritoneal serous or papillary carcinoma of ovary 0·08 0·08–0·09 1280 415 21·9% 19·1–25·2 1280
Mullerian mixed tumour of ovary 0·14 0·14–0·15 2255 730 21·4% 19·5–23·6 2242
Adenocarcinoma with variant of fallopian tube 0·17 0·16–0·18 2683 869 59·1% 56·8–61·6 2672
Non-epithelial tumours of ovary 0·25 0·25–0·26 3977 1288 82·0% 80·6–83·5 3970
Sex cord tumours of ovary 0·13 0·12–0·13 2006 650 78·8% 76·5–81·1 1998
Malignant or immature teratomas of ovary 0·05 0·05–0·06 833 270 83·4% 80·6–86·3 829
Germ cell tumour of ovary 0·07 0·07–0·08 1138 369 86·6% 84·4–88·8 1143
Epithelial tumours of vulva and vagina 1·97 1·95–2·00 30 938 11 215 58·1% 57·3–58·8 30 238
Squamous cell carcinoma with variants of vulva and vagina 1·69 1·67–1·71 26 422 8558 59·8% 59·0–60·7 26 277
Adenocarcinoma with variants of vulva and vagina 0·07 0·07–0·08 1120 363 45·8% 42·3–49·6 1112
Paget’s disease of vulva and vagina 0·05 0·04–0·05 746 242 88·0% 83·7–92·6 744
Undifferentiated carcinoma of vulva and vagina 0·01 0·00–0·01 85 28 25·6% 15·8–41·6 85
Trophoblastic tumour of placenta 0·02 0·02–0·03 363 100 89·3% 85·3–92·2 361
Choriocarcinoma of placenta 0·02 0·02–0·02 352 114 89·8% 86·5–93·3 350
(Table 1 continues on next page)
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Rare: male genital and urogenital cancers 7·09 7·05–7·14 111 128 38 138 73·6% 73·3–74·0 109 102
Rare epithelial tumours of prostate 0·60 0·59–0·61 9437 3563 75·4% 74·0–76·9 9291
Squamous cell carcinoma with variants of prostate 0·02 0·02–0·02 291 94 41·1% 34·1–49·5 287
Infiltrating duct carcinoma of prostate 0·51 0·50–0·53 8064 2612 78·7% 77·2–80·3 7945
Transitional cell carcinoma of prostate 0·06 0·06–0·07 960 311 57·7% 53·4–62·4 941
Salivary-gland-type tumours of prostate 0·01 0·01–0·01 122 40 78·5% 64·4–95·7 118
Testicular and paratesticular cancers 3·29 3·27–3·32 51 605 16 061 94·9% 94·7–95·2 51 011
Paratesticular adenocarcinoma with variants 0·00 0·00–0·00 22 7 82·5% 65·3–104·1 22
Non-seminomatous testicular cancer 1·27 1·25–1·28 19 835 6425 92·9% 92·5–93·3 19 714
Seminomatous testicular cancer 1·82 1·80–1·84 28 516 9236 97·5% 97·3–97·8 28 326
Spermatocytic seminoma 0·03 0·03–0·03 502 163 95·3% 91·8–99·0 502
Teratoma with malignant transformation 0·00 0·00–0·00 20 6 91·4% 78·6–106·2 20
Testicular sex cord cancer 0·02 0·02–0·02 340 110 82·3% 77·3–87·6 337
Epithelial tumours of penis 0·66 0·65–0·67 10 368 3887 67·5% 66·2–68·9 10 210
Squamous cell carcinoma with variants of penis 0·62 0·60–0·63 9646 3124 68·9% 67·5–70·2 9621
Adenocarcinoma with variants of penis 0·01 0·00–0·01 88 29 49·0% 36·2–66·4 86
Rare epithelial tumours of kidney 0·05 0·04–0·05 723 261 18·8% 15·8–22·4 704
Squamous cell carcinoma spindle cell type of kidney 0·01 0·01–0·01 190 62 22·0% 16·0–30·2 190
Squamous cell carcinoma with variants of kidney 0·03 0·03–0·04 533 173 17·7% 14·4–21·7 514
Epithelial tumours of pelvis and ureter 1·58 1·57–1·60 24 826 9187 48·8% 48·0–49·7 24 017
Transitional cell carcinoma of pelvis and ureter 1·41 1·39–1·43 22 099 7158 51·3% 50·4–52·2 21 607
Squamous cell carcinoma with variants of pelvis and ureter 0·02 0·02–0·03 372 121 15·0% 11·2–20·2 366
Adenocarcinoma with variants of pelvis and ureter 0·02 0·02–0·02 326 106 43·0% 36·7–50·5 320
Epithelial tumours of urethra 0·13 0·13–0·14 2077 784 44·5% 41·6–47·5 2050
Transitional cell carcinoma of urethra 0·09 0·08–0·09 1390 450 42·9% 39·5–46·7 1387
Squamous cell carcinoma with variants of urethra 0·02 0·02–0·02 329 107 51·1% 44·6–58·5 329
Adenocarcinoma with variants of urethra 0·01 0·01–0·01 190 62 52·0% 43·2–62·6 189
Rare epithelial tumours of bladder 0·65 0·64–0·67 10 226 3819 32·3% 31·2–33·5 10 152
Squamous cell carcinoma with variants of bladder 0·36 0·35–0·36 5566 1803 24·3 22·9–25·7 5534
Adenocarcinoma with variants of bladder 0·30 0·29–0·31 4653 1507 41·9% 40·1–43·8 4614
Salivary-gland-type tumours of bladder 0·00 0·00–0·00 7 2 NE NE 7
Extragonadal germ cell tumours 0·12 0·11–0·12 1862 576 69·6% 67·3–71·8 1851
Non-seminomatous germ cell tumours 0·06 0·05–0·06 915 296 62·5% 59·2–66·0 909
Seminomatous germ cell tumours 0·01 0·01–0·01 130 42 85·9% 79·1–93·3 130
Germ cell tumours of CNS 0·04 0·03–0·04 574 186 82·5% 79·2–85·9 572
Rare: neuroendocrine tumours 3·51 3·43–3·58 54 942 19 587 53·5% 53·0–54·1 54 331
GEP, well differentiated not functioning endocrine carcinoma of 
pancreas and digestive tract
1·01 1·00–1·03 15 852 5134 72·0% 71·1–73·0 15 656
GEP, well differentiated functioning endocrine carcinoma of 
pancreas and digestive tract
0·03 0·02–0·03 411 133 61·3% 55·9–67·3 407
GEP, poorly differentiated endocrine carcinoma 0·67 0·65–0·68 10 421 3375 35·0% 33·9–36·2 10 456
GEP, mixed endocrine–exocrine carcinoma 0·01 0·01–0·01 147 48 25·9% 18·2–37·0 141
Endocrine carcinoma of thyroid gland 0·24 0·23–0·25 3796 1230 83·6% 82·1–85·2 3793
Neuroendocrine carcinoma of skin 0·19 0·19–0·20 3024 979 55·9% 53·2–58·7 2997
Typical and atypical carcinoid of the lung 0·39 0·38–0·40 6160 1995 81·1% 79·9–82·5 6058
Neuroendocrine carcinoma of other sites 0·90 0·89–0·92 14 120 4573 23·9% 23·0–24·8 13 958
Pheochromocytoma, malignant 0·04 0·04–0·04 650 211 70·1% 65·9–74·5 612
Paraganglioma 0·02 0·02–0·02 347 112 56·3% 50·6–62·6 342
(Table 1 continues on next page)
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Rare: cancers of the endocrine organs 5·35 5·32–5·39 83 836 28 322 88·1% 87·8–88·4 82 523
Carcinomas of pituitary gland 0·04 0·03–0·04 582 206 63·7% 58·9–69·0 511
Carcinomas of thyroid gland 5·07 5·03–5·10 79 418 26 768 90·5% 90·2–90·8 78 533
Carcinomas of parathyroid gland 0·03 0·02–0·03 410 143 80·8% 75·8–86·2 395
Carcinomas of adrenal gland 0·22 0·21–0·23 3424 1205 32·1% 30·2–34·0 3103
Rare: sarcomas 5·86 5·83–6·00 91 878 31 916 59·5% 57·4–58·2 90 568
Soft tissue sarcoma 4·71 4·68–4·74 73 795 25 851 56·7% 56·3–57·1 72 696
Soft tissue sarcoma of head and neck 0·26 0·25–0·27 4087 1324 59·8% 57·7–61·8 4062
Soft tissue sarcoma of limbs 1·10 1·08–1·11 17 178 5564 67·7% 66·8–68·6 17 094
Soft tissue sarcoma of superficial trunk 0·50 0·49–0·51 7813 2531 48·1% 46·8–49·5 7723
Soft tissue sarcoma of mediastinum 0·03 0·03–0·03 465 151 23·4% 19·3–28·3 457
Soft tissue sarcoma of heart 0·01 0·01–0·02 216 70 14·4% 9·8–21·0 203
Soft tissue sarcoma of breast 0·18 0·18–0·19 2865 928 74·5% 72·5–76·5 2864
Soft tissue sarcoma of uterus 0·55 0·54–0·56 8657 2804 52·0% 50·8–53·2 8568
Other soft tissue sarcomas of genitourinary tract 0·20 0·19–0·21 3160 1024 50·4% 48·3–52·5 3107
Soft tissue sarcoma of viscera 0·38 0·37–0·39 6004 1945 42·1% 40·6–43·6 5915
Soft tissue sarcoma of paratestis 0·03 0·03–0·04 510 165 87·2% 82·2–92·4 510
Soft tissue sarcoma of retroperitoneum and peritoneum 0·31 0·30–0·32 4911 1591 38·8% 37·1–40·5 4854
Soft tissue sarcoma of pelvis 0·20 0·19–0·20 3090 1001 47·4% 45·3–49·6 3064
Soft tissue sarcoma of skin 0·30 0·29–0·31 4737 1534 90·2% 88·8–91·7 4728
Soft tissue sarcoma of paraorbit 0·01 0·01–0·01 117 38 63·3% 52·9–75·7 115
Soft tissue sarcoma of brain and other parts of nervous system 0·17 0·17–0·18 2723 882 54·5% 52·3–56·7 2695
Embryonal rhabdomyosarcoma of soft tissue 0·05 0·05–0·06 836 271 66·2% 62·8–69·8 825
Alveolar rhabdomyosarcoma of soft tissue 0·03 0·03–0·04 519 168 36·0% 31·7–40·8 515
Ewing’s sarcoma of soft tissue 0·06 0·06–0·07 998 323 44·9% 41·5–48·5 992
Bone sarcoma 0·85 0·84–0·87 13 376 4382 58·6% 57·6–59·6 13 216
Osteogenic sarcoma 0·21 0·21–0·22 3330 1079 51·4% 49·5–53·4 3282
Chondrogenic sarcomas 0·26 0·25–0·27 4107 1330 70·0% 68·2–71·7 4060
Notochordal sarcomas, chordoma 0·07 0·07–0·08 1145 371 62·5% 58·2–67·2 755
Vascular sarcomas 0·01 0·01–0·01 129 42 45·1% 36·4–55·9 129
Ewing’s sarcoma 0·12 0·12–0·13 1943 629 52·8% 50·4–55·3 1932
Epithelial tumours, adamantinoma 0·01 0·01–0·02 213 69 87·2% 81·0–93·9 210
Other high grade sarcomas (fibrosarcoma, malignant fibrous 
histiocytoma)
0·02 0·02–0·02 304 98 46·2% 40·1–53·1 302
Gastrointestinal stromal sarcoma 0·30 0·29–0·31 4706 1683 72·3% 70·4–74·1 4781
Rare: cancers of the CNS 7·56 7·51–8·00 118 391 36 343 21·3% 21·0–21·6 111 838
Tumours of CNS 7·36 7·32–7·40 115 289 35 339 20·3% 20·0–20·6 108 752
 Astrocytic tumours of CNS 4·99 4·95–5·02 78 118 25 303 15·0% 14·8–15·3 77 195
Oligodendroglial tumours of CNS 0·39 0·38–0·40 6148 1991 51·8% 50·4–53·3 6124
Ependymal tumours of CNS 0·21 0·20–0·21 3212 1040 72·7% 71·0–74·5 3190
Choroid plexus carcinoma of CNS 0·01 0·01–0·01 98 32 57·7% 48·3–68·8 95
Malignant meningiomas 0·16 0·16–0·17 2564 830 61·1% 58·8–63·4 2509
Embryonal tumours of CNS 0·20 0·19–0·21 3102 1005 56·1% 54·2–58·1 3092
Rare: skin cancers and non-cutaneous melanoma 1·22 1·18–1·25 21 878 7086 70·2% 69·3–71·1 21 637
Malignant melanoma of mucosa 0·15 0·14–0·15 2279 738 20·3% 18·3–22·6 2277
Malignant melanoma of uvea 0·70 0·69–0·72 11 022 3570 71·0% 69·8–72·2 10 872
Adnexal carcinoma of skin 0·30 0·29–0·31 4684 1517 86·1% 83·9–88·0 4661
Kaposi’s sarcoma 0·25 0·24–0·26 3893 1261 78·9% 77·1–80·8 3830
(Table 1 continues on next page)
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Rare: embryonal tumours 0·34 0·33–0·35 5363 1822 78·6% 77·4–79·8 5239
Neuroblastoma and ganglioneuroblastoma 0·10 0·10–0·11 1566 507 64·6% 62·1–67·3 1553
Nephroblastoma 0·13 0·12–0·13 1965 636 88·2% 86·6–89·7 1936
Retinoblastoma 0·05 0·05–0·06 860 279 96·5% 95·1–97·9 801
Hepatoblastoma 0·02 0·02–0·03 357 116 76·8% 72·2–81·7 352
Pleuropulmonary blastoma 0·00 0·00–0·00 9 3 53·5% 28·3–101·1 9
Pancreatoblastoma 0·00 0·00–0·00 39 13 34·3% 20·7–56·9 35
Olfactory neuroblastoma 0·03 0·03–0·03 498 161 64·0% 59·2–69·2 489
Odontogenic malignant tumours 0·00 0·00–0·01 69 22 61·6% 49·0–77·5 69
Rare: haematological malignancies 27·73 27·65–27·82 434 469 156 099 50·5% 50·3–50·7 423 741
Rare lymphoid diseases 18·09 18·02–18·16 283 399 100 343 55·8% 55·5–56·0 279 794
Hodgkin’s lymphoma, classical 2·46 2·44–2·49 38 588 12 499 81·4% 80·9–81·8 38 389
Hodgkin’s lymphoma nodular lymphocyte predominance 0·09 0·09–0·10 1483 480 93·6% 91·8–95·3 1507
Precursor B-cell or T-cell lymphoblastic leukaemia or 
lymphoma (and Burkitt’s leukaemia or lymphoma)
1·46 1·44–1·47 22 795 7383 58·1% 57·4–58·8 22 496
T-cell cutaneous lymphoma (Sezary syndrome, mycosis 
fungoides)
0·35 0·34–0·36 5526 1790 81·5% 80·0–83·1 5482
Other T-cell lymphomas and natural killer cell neoplasms 0·62 0·60–0·63 9656 3128 39·0% 37·9–40·2 9635
Diffuse B-cell lymphoma 4·32 4·29–4·35 67 645 21 910 53·4% 52·9–53·9 67 907
Follicular B-cell lymphoma 2·19 2·17–2·22 34 346 11 125 77·0% 76·4–77·6 34 545
Hairy cell leukaemia 0·28 0·27–0·29 4375 1417 89·8% 88·3–91·3 4387
Plasmacytoma or multiple myeloma (and heavy chain diseases) 5·71 5·67–5·75 89 440 28 970 35·3% 34·8–35·7 86 496
Mantle cell lymphoma 0·56 0·55–0·57 8748 2834 44·0% 42·6–45·4 8797
Prolymphocytic leukaemia, B cell 0·05 0·05–0·06 804 260 30·8% 26·9–35·2 788
Acute myeloid leukaemia and related precursor neoplasms 3·81 3·77–3·84 59 608 21 557 19·2% 18·8–19·6 56 709
Acute promyelocytic leukaemia with t(15;17) with variants 0·12 0·11–0·13 1876 608 63·2% 60·8–65·7 1880
Acute myeloid leukaemia 3·50 3·47–3·53 54 789 17 746 17·5% 17·1–17·8 52 305
Myeloproliferative neoplasms 3·31 3·28–3·34 51 888 18 805 68·3% 67·7–68·9 50 624
Chronic myeloid leukaemia 1·12 1·10–1·13 17 473 5660 54·9% 54·0–55·9 16 599
Other myeloproliferative neoplasms 2·17 2·14–2·19 33 954 10 998 75·0% 74·3–75·7 33 599
Mast cell tumour 0·03 0·03–0·03 461 149 71·4% 66·2–77·1 454
Myelodysplastic syndrome and myelodysplastic or 
myeloproliferative diseases
2·47 2·45–2·50 38 738 15 116 31·1% 30·5–31·8 37 792
Myelodysplastic syndrome with 5q syndrome 0·01 0·01–0·01 156 51 48·0% 38·3–60·3 178
Other myelodysplastic syndrome 2·14 2·12–2·16 33 542 10 864 32·2% 31·5–32·9 32 576
Chronic myelomonocytic leukaemia 0·29 0·28–0·30 4542 1471 21·3% 19·8–23·0 4575
Atypical chronic myeloid leukaemia BCR/ABL negative 0·02 0·01–0·02 239 77 28·2% 21·7–36·5 248
Histiocytic and dendritic cell neoplasms 0·05 0·05–0·06 828 278 59·9% 56·1–63·9 817
Histiocytic malignancies 0·04 0·04–0·05 656 212 63·4% 59·4–67·8 645
Lymph-node accessory cell tumours 0·01 0·01–0·01 172 56 45·6% 37·1–56·0 172
All rare tier 2 tumours 114·99 114·82–115·16 1 801 443 636 753 48·5% 48·4–48·6 1 751 601
Common: digestive tumours 91·80 91·65–91·95 1 438 094 490 051 41·4% 41·3–45·8 1 365 575
Epithelial tumours of stomach 17·10 17·03–17·16 267 832 92 067 21·2% 21·0–21·4 253 439
Adenocarcinoma with variants of stomach 14·18 14·12–14·24 222 145 71 954 22·7% 22·5–22·9 221 604
Epithelial tumours of colon 43·88 43·77–43·98 687 386 234 319 54·2% 54·0–54·4 664 118
Adenocarcinoma with variants of colon 38·85 38·75–38·95 608 637 197 139 57·9% 57·7–58·0 604 459
Epithelial tumours of rectum 17·98 17·92–18·05 281 697 95 187 53·8% 53·6–54·1 276 024
Adenocarcinoma with variants of rectum 16·45 16·39–16·52 257 723 83 477 55·8% 55·6–56·1 258 469
Epithelial tumours of pancreas 12·84 12·79–12·90 201 179 68 478 4·1% 4·0–4·2 182 579
Adenocarcinoma with variants of pancreas 7·96 7·92–8·01 124 744 40 405 4·1% 4·0–4·2 119 154
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genital and urological tumours, endocrine organ 
tumours, CNS tumours, and sarcomas had overall 
incidences from 4 to 8 per 100 000 people per year. Rare 
skin cancers and non­cutaneous melanoma, and 
embryonal cancers were the families with the lowest 
incidences (1·22 and 0·34 per 100 000). Overall, rare 
cancers accounted for 24% of all cancers diagnosed in 
EU28 during 2000–07; the majority were solid 
cancers (76%). For sex­specific rare cancers, we also 
provide sex­specific incidence (appendix p 4).
5­year relative survival of all rare cancers was 48·5% 
(95% CI 48·4–48·6), compared with 63·4% (95% CI 
63·3–63·4) for all common cancers. Rare cancers also 
had lower survival within the families of digestive cancers 
(15·3% [95% CI 15·2–15·5] for rare cancers vs 41·4% 
[41·3–41·5] for common cancers), female genital cancers 
(57·7% [57·5–57·9] vs 82·2% [82·1–82·3]), male genital 
and urological cancers (73·6% [73·3–74·0] vs 75·9% 
[75·8–76·0]), skin cancers (70·2% [69·3–71·1] vs 95·6% 
[95% CI 95·5–95·7]), and haematological tumours 
(50·5% [50·3–50·7] vs 60·5% [60·2–60·8]). The only 
exception was the thoracic cancer family (13·4% 
[13·1–13·6] vs 10·1% [10·0–10·2]), for which common 
cancers included poorly differentiated endocrine 
carcinoma of the lung with a very poor prognosis (5·9% 
[5·7–6·0] after 5 years. Families including only rare 
cancers had 5­year relative survival ranging from high, as 
for embryonal tumours (78·6% [95% CI 77·4–79·8]) and 
endocrine organ tumours (88·1% [87·8–88·4]), to 
intermediate, for sarcomas (59·5% [57·4–58·2]), neuro­
endocrine tumours (53·5% [53·0–54·1]), and head and 
neck tumours (52·1% [51·8–52·3]), and low for CNS 
tumours (21·3% [21·0–21·6]).
Time trends of incidence and survival for rare cancers 
are in figures 1 and 2. Cancers whose incidence variation 
fell outside the confidence interval shown in figure 1 are 
listed in table 2, with the age­standardised incidence 
estimates for 1999–2002 and 2003–07, the corresponding 
annual percentage change and 3 standard­error confidence 
intervals. Rare cancer dots in the plot seem to be 
Crude incidence 
rate per 
100 000 people 
per year
95% CI Observed cases 
in 83 cancer 
registries in 
2000–07
Estimated 
new cases in 
2013 in EU28
5-year 
relative 
survival (%)
95% CI Observed cases 
in 94 cancer 
registries in 
2000–07
(Continued from previous page)
Common: thoracic tumours 53·02 52·91–53·14 830 611 281 332 10·1% 10·0–10·2 779 539
Epithelial tumour of lung 53·02 52·91–53·14 830 611 281 332 10·1% 10·0–10·2 779 539
Squamous cell carcinoma with variants of lung 12·31 12·25–12·36 192 771 62 439 13·8% 13·6–14·0 190 051
Adenocarcinoma with variants of lung 11·63 11·58–11·68 182 175 59 007 16·0% 15·8–16·2 179 385
Poorly differentiated endocrine carcinoma of lung 7·91 7·86–7·95 123 888 40 128 5·9% 5·7–6·0 121 904
Common: female genital tumours 74·17 74·03–74·30 1 161 864 394 087 82·2% 82·1–82·3 1 131 902
Epithelial tumours of breast 63·52 63·40–63·65 995 119 318 878 82·4% 82·3–82·5 961 378
Invasive ductal carcinoma of breast 46·56 46·45–46·66 729 345 236 237 85·4% 85·3–85·6 723 998
Invasive lobular carcinoma of breast 7·75 7·71–7·80 121 455 39 340 86·2% 85·9–86·5 120 973
Epithelial tumours of corpus uteri 10·64 10·59–10·70 166 745 75 209 81·2% 80·9–81·4 164 787
Adenocarcinoma with variants of corpus uteri 9·93 9·88–9·98 155 550 50 383 83·0% 82·7–83·2 154 968
Common: male genital and urogenital tumours 85·27 85·13–85·42 1 335 876 462 665 75·9% 75·8–76·0 1 277 743
Epithelial tumours of prostate 55·06 54·95–55·18 862 576 301 113 84·0% 83·8–84·1 842 467
Adenocarcinoma with variants of prostate 48·86 48·75–48·97 765 405 247 917 88·1% 88·0–88·3 762 360
Epithelial tumours of kidney 12·66 12·61–12·72 198 402 65 848 60·5% 60·2–60·7 187 324
Renal cell carcinoma with variants 10·08 10·03–10·13 157 886 51 140 68·5% 68·2–68·8 153 460
Epithelial tumours of bladder 17·55 17·48–17·61 274 896 95 704 60·4% 60·1–60·6 266 941
Transitional cell carcinoma of bladder 15·68 15·62–15·74 245 681 79 577 62·7% 62·4–63·0 243 620
Common: skin tumours and non-cutaneous melanoma 69·08 68·95–69·21 1 082 244 350 542 95·6% 95·5–95·7 1 048 046
Malignant skin melanoma 14·06 14·00–14·12 220 206 71 325 83·8% 83·6–84·1 216 317
Epithelial tumours of skin 55·03 54·91–55·14 862 038 279 217 98·8% 98·7–99·0 837 895
Basal cell carcinoma of skin 40·75 40·65–40·85 638 347 206 763 101·6% 101·5–101·8 634 953
Squamous cell carcinoma with variants of skin 14·28 14·22–14·34 223 691 72 454 89·7% 89·4–90·1 221 487
Common: haematological malignancies 11·03 10·98–11·08 172 794 58 286 60·5% 60·2–60·8 166 040
Lymphoid diseases 11·03 10·98–11·08 172 794 58 286 60·5% 60·2–60·8 166 040
Other non-Hodgkin, mature B-cell lymphoma 6·37 6·33–6·41 99 729 32 303 68·3% 67·8–68·7 97 389
All common tumours 384·37 384·07–384·78 6 021 483 2 036 963 63·4% 63·3–63·4 5 633 710
The first tier entities are not a sum of the second tiers included because of the not otherwise specified entities. EU28=European Union (28 member states). GEP=gastroenteric-pancreatic tumour. NE=not estimable. 
Table 1: Estimates of incidence and survival for rare and common cancers
See Online for appendix
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distributed fairly symmetrically around the zero­change 
line, indicating no major systematic shifts in incidence. 
The average annual percentage change of all rare cancers 
was 0·5% (99·8% CI 0·3–0·8). Incidence increased for 16 
rare cancers and incidence decreased for 10 rare cancers, 
but with changes falling outside the 99·8% confidence 
limits. Time trends of rare cancers did not substantially 
differ from those of common cancers (data not shown), 
whose average annual change was 0·9%. Only prostate 
and skin cancers had an annual percentage change of 
more than 2%, while only epithelial cancers of the 
stomach decreased more than 2% (data not shown).
Survival increased from 1999–2001 to 2005–07 for most 
rare cancers. The cloud of points in figure 2 is skewed 
upward from the zero line, corresponding to a mean 
increase in survival, averaged over all the entities, of 
2·9% (95% CI 2·7–3·2). Survival for 24 rare cancers was 
significantly increased (table 3), whereas survival was 
significantly reduced for only one cancer (other 
myelodysplastic syndromes). Rare cancers with the 
largest survival increases were mainly haematological: 
chronic myeloid leukaemia, diffuse B cell lymphoma, 
follicular lym phoma, precursor B/T cell lymphoblastic 
leukaemia or lymphoma, and multiple myeloma. 
Sarcomas were well represented among the top tumours 
with increasing survival, specifically of the viscera, 
trunk, and Kaposi’s sarcoma. Survival increases higher 
than 5 percentage points were also observed for 
infiltrating ductal carcinoma of the prostate 
(12·3  percentage points [99·8% CI 6·4–18·2]), poorly 
differentiated endocrine carcinoma of the digestive 
system (7·5 percentage points [2·7–12·2]), and 
squamous cell carcinoma of the oropharynx 
(7·1 percentage points [5·0–9·2]). There were no major 
improvements in survival for rare cancers of the colon, 
rectum, breast, or kidney, differently from the 
corresponding groups of common cancers.8
The extent of centralisation of rare cancer treatment 
is presented in figures 3 and 4 presenting mean admission 
volume, overall and by country, for 38 cancer groups 
ranked by decreasing incidence. We used a logarithmic 
scale for the x­axis to make the graph readable despite 
large mean admission volume variability (from 0·2 to 82·6 
treatments per year) across the considered cancers. The 
mean number of admissions is in the appendix (p 3–4). 
Pooled mean admission volume (figures 3 and 4) ranged 
from a maximum of 82·6 treatments per year for head 
and neck tumours to less than 0·5 treatments per year for 
placenta (choriocarcinoma), and some embryonal and 
endocrine tumours. The higher the incidence, the larger 
the mean admission volume of treating hospitals. The 
association between cancer incidence and mean 
admission volume in the pool of countries was very 
strong (Pearson’s correlation coefficient 0·88), although 
there are several outliers. For example, epithelial tumours 
of the ovary had a higher incidence but a lower mean 
admission volume than CNS tumours (35 vs 20 cases 
treated per year). Treatment of patients with epithelial 
tumours of the ovary was thus spread among a larger 
number of hospitals compared with CNS tumours. 
Similarly, the incidence of soft tissue sarcomas was 
5 times higher than bone sarcomas, but soft tissue 
sarcomas were treated centrally less  than bone sarcoma. 
Treatment for thyroid cancers, uveal melanoma, and 
several embryonal tumours appeared to be fairly 
concentrated in a few hospitals with relatively 
high volumes. By contrast, tumours of the urinary tract, 
gastro entero pancreatic neuroendocrine tumours, 
small intestine, non­epithelial ovary cancers, and 
Figure 1: Annual percentage changes in age-adjusted incidence rates of rare 
cancers (1999–2007)
Funnel plot in which each dot represents a single rare cancer, the y-axis displays 
the estimated difference in terms of annual percentage change of age-adjusted 
incidence, and the x-axis the corresponding precision in terms of the inverse of 
its standard error. 3 standard-error confidence bounds for estimated zero 
changes7 are represented by two symmetrical lines progressively approaching 
the x-axis with increasing x values. Dots lying above or below the area between 
them correspond respectively to tumours with 99·8% significantly higher or 
lower incidence rates.
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Figure 2: Difference in 5-year relative survival for rare cancers (1999–2001 vs 
2005–07) 
Funnel plot in which each dot represents a single rare cancer, the y-axis displays 
the estimated difference between 5-year relative survival in 2005–07 and 
1999–2001, and the x-axis the corresponding precision in terms of the inverse of 
its standard error. 3 standard-error confidence bounds for estimated zero 
changes7 are represented by two symmetrical lines progressively approaching the 
x-axis with increasing x values. Dots lying above or below the area between them 
correspond respectively to tumours with 99·8% significantly higher or lower 
incidence rates. 
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neuroendocrine tumours of the skin were treated in 
centres with an even lower mean admission volume than 
would be expected because of their very low occurrence.
With some exceptions, country­specific patterns of 
mean admission volume were similar to the pooled data. 
By contrast with what was found in the other countries, 
the management of epithelial ovarian cancers was highly 
centralised in Bulgaria and Slovenia. Patients with CNS 
tumours were treated in highly centralised structures in 
all countries except Finland and Navarra. Treatment for 
uveal melanoma and retinoblastoma was not centralised 
in Bulgaria or in Navarra. Slovenia and the Netherlands 
had the highest centralisation patterns, whereas mean 
admission volume for the majority of cancers was very 
low in Navarra due also to the small population size.
Table 4 shows the annual number of cases diagnosed, 
the number of top­volume hospitals treating at least 75% 
of national cases, and the average annual numbers of 
treatments provided for each country and for 29 rare 
cancers. For head and neck cancers, 75% of patients 
were centralised in two top hospitals in Slovenia 
(2 million population, 266 treatments per hospital per 
year), and 12 top hospitals in the Netherlands (17 million 
population, 201 treatments per hospital per year). The 
level of centralisation was lower in the other countries, 
resulting in a caseload of 145 in the ten Bulgarian top 
hospitals, 106 in the 29 Belgian hospitals, and 83 in the 
six hospitals in Finland, 77 in the two hospitals in 
Navarra, and 63 in the seven hospitals in Ireland. The 
Netherlands and Slovenia had the highest treatment 
volume for 12 of 29 cancers.
Discussion
Rare cancers make up one quarter of all malignancies. 
They are a very heterogeneous group of almost 
200 cancers, mostly solid, constituting from 2% of all 
skin cancers up to 32% of all female genital cancers. 
We confirmed that 5­year survival is lower for rare 
cancers than common cancers (49% vs 63%), and for all 
rare cancer families compared with their more common 
counterparts, except thoracic cancers. The disadvantage 
persisted even after excluding common cancers with 
good prognosis, such as prostate, breast, and skin cancer. 
Several factors help explain these differences: the biology 
1999–2002 
age-standardised 
incidence
2003–07 
age-standardised 
incidence
Annual 
percentage 
change
99·8% CI
Gastrointestinal stromal sarcoma 0·098 0·258 24·1% 12·0 to 36·2
Gastroenteric-pancreatic tumour, poorly differentiated endocrine 
carcinoma of pancreas and digestive system
0·361 0·618 12·7% 7·7 to 17·8
Other T-cell lymphomas and natural killer cell neoplasms 0·395 0·555 7·8% 3·3 to 12·4
Diffuse B-cell lymphoma 2·837 3·894 7·3% 5·7 to 8·9
Other myeloproliferative neoplasms 1·530 2·092 7·2% 5·0 to 9·4
Mantle cell lymphoma 0·367 0·477 6·0% 1·6 to 10·4
Carcinomas of thyroid gland 3·470 4·353 5·2% 3·7 to 6·6
Other myelodysplastic syndrome 1·395 1·738 5·0% 3·0 to 7·1
Squamous cell carcinoma with variants of anal canal 0·595 0·728 4·6% 1·2 to 8·0
Follicular B-cell lymphoma 1·676 2·021 4·2% 2·2 to 6·3
Cholangiocarcinoma of intrahepatic bile tract 0·685 0·816 4·0% 0·9 to 7·0
Neuroendocrine carcinoma of other sites 0·683 0·801 3·6% 0·5 to 6·7
Adenocarcinoma with variants of oesophagus 2·725 3·153 3·3% 1·8 to 4·8
Squamous cell carcinoma with variants of oropharynx 2·412 2·732 2·8% 1·1 to 4·5
Adenocarcinoma with variants of extrahepatic biliary tract 0·969 1·088 2·6 0·1 to 5·1
Hepatocellular carcinoma of liver and intrahepatic bile tract 2·068 2·273 2·1% 0·4 to 3·8
Squamous cell carcinoma with variants of cervix uteri 4·536 4·287 –1·2% –2·4 to –0·1
Adenocarcinoma with variants of ovary 5·351 5·053 –1·3% –2·3 to –0·2
Squamous cell carcinoma with variants of larynx 3·853 3·578 –1·6% –2·8 to –0·4
Chronic myeloid leukaemia 0·991 0·854 –3·2% –5·5 to –0·9
Infiltrating duct carcinoma of prostate 0·412 0·343 –4·0% –7·4 to –0·6
Squamous cell carcinoma with variants of lip 0·838 0·693 –4·1% –6·5 to –1·8
Large cell carcinoma of lung 3·440 2·806 –4·4% –5·6 to –3·2
Mucinous adenocarcinoma of ovary 0·813 0·657 –4·6% –7·2 to –2·1
Adenocarcinoma with variants of bladder 0·265 0·213 –4·7% –8·9 to –0·5
Undifferentiated carcinoma of stomach 0·189 0·123 –9·2% –13·9 to –4·5
Data are rare cancers lying outside the 3 standard-error confidence bounds in figure 1.
Table 2: Age-standardised incidence in 1999–2002 and 2003–07
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of the diseases, adequacies of diagnosis and treatment, 
scarcity of effective therapies, or insufficient evidence­
based treatment guidelines.
A novelty of this study is the analysis of incidence and 
survival trends. Overall, incidence rose by 0·5% a year 
from 1999 up to 2007. The increase was substantial for 
several rare cancers. Some of the increases can probably 
be attributed to improvements in pathological 
diagnosis, new entity codes in the ICD­O­3, and to the 
time needed to adapt the coding procedures. This is the 
case for gastrointestinal stromal tumours, large cell 
carcinomas of the lung, neuroendocrine tumours, and 
many haematological cancers.9–11 For other rare cancers, 
increases in incidence might be due to improvements 
in pathological diagnosis, similar to neuroendocrine 
tumours. For thyroid carcinoma several authors have 
suggested an increase in overdiagnosis.12 However, 
increased exposure to risk factors might explain higher 
incidence rates for some cancers; such as exposure to 
HPV for oropharynx and anal canal squamous cell 
cancers13,14 and perhaps increasing obesity or gastro­
oesophageal reflux for adenocarcinoma of the 
oesophagus.15 The low incidence of squamous cell 
carcinoma of the cervix might reflect organised cervical 
screening programmes. The drop in incidence for some 
of the rare cancers was due to the still falling prevalence 
of smoking.16
Relative survival improved by about 3% overall over the 
study period, slightly less than for common cancers (5·5%, 
data not shown), suggesting that investments were more 
focused on common cancers. Also, overdiagnosis is 
expected to affect more common cancers than rare cancers. 
Improvement to relative survival was greatest for chronic 
myeloid leukaemia with a 5­year gain in survival of 
21% across the study years, largely explained by the 
widespread use of new and more effective treatments, 
such as targeted treatments and more effective stem­cell 
transplantation.17 For many other haematological cancers, 
new (targeted) drugs in combination with radiotherapy, 
and improvements in transplantation are responsible for 
the effects on prognosis.18 Survival also improved for some 
groups of sarcoma (viscera, trunk, and limbs) for which 
multidisciplinary approaches and centralisation of 
treatments might take the credit; similarly, for neuro­
endocrine tumours,19 biliary tract, liver,20 and oesophageal 
cancers,15 for which there are now more specific and 
effective treatments and protocols. For oesophageal 
cancers, earlier detection through Barrett’s oesophagus 
surveillance practices might also contribute to 
improvements in relative survival. For oropharyngeal 
cancers, the larger proportion of less aggressive tumours 
attributed to HPV might have influenced the survival 
gain.21 For carcinoma of the thyroid and infiltrating ductal 
carcinoma of the prostate, early diagnosis is probably the 
major contributing factor to improved relative survival. 
Early diagnosis would also have contributed to a rise in the 
proportion of cases that are clinically irrelevant, although 
this is hard to estimate.12,22 As for incidence, some of the 
apparent survival gains might be due to classification 
changes,9 such as for large cell carcinomas of the lung that 
have a relatively new ICD­O morphology code.
Myeloproliferative neoplasms and myelodysplastic 
syndromes were not considered cancers until the WHO 
classification was changed in 2001, and their registration 
started even later.9 Generally, the increases in incidence 
of some rare cancers could be due to more specific 
diagnosis and coding by cancer registry.
Our hospital volume analysis represents, to our 
knowledge, the first attempt to systematically study the 
place of treatment of rare cancers from population­based 
cancer registry data. Many potentially relevant indications 
1999–2001 
5-year 
relative 
survival
2005–07 
5-year 
relative 
survival
Difference 99·8% CI
Chronic myeloid leukaemia 37·2 57·9 20·7 17·4 to 24·1
Infiltrating duct carcinoma of prostate 67·5 79·8 12·3 6·4 to 18·2
Soft tissue sarcoma of viscera 34·7 43·7 9·0 3·6 to 14·4
Kaposi’s sarcoma 75·4 84·2 8·8 1·4 to 16·2
Diffuse B-cell lymphoma 46·9 55·2 8·4 6·5 to 10·2
Follicular B-cell lymphoma 69·5 77·9 8·4 5·9 to 10·8
Poorly differentiated endocrine carcinoma of 
pancreas and digestive system
25·3 32·7 7·5 2·7 to 12·2
Squamous cell carcinoma with variants of oropharynx 37·5 44·5 7·1 5·0 to 9·2
Soft tissue sarcoma of superficial trunk 43·9 50·4 6·5 1·4 to 11·6
Precursor B/T cell lymphoblastic leukaemia or 
lymphoma (and Burkitt’s leukaemia/lymphoma)
54·3 60·8 6·4 3·8 to 9·1
Plasmacytoma or multiple myeloma (and heavy chain 
diseases)
29·8 35·0 5·2 3·8 to 6·7
Carcinomas of thyroid gland 85·6 90·6 5·0 3·8 to 6·3
Adenocarcinoma with variants of cervix uteri 63·8 68·8 5·0 1·7 to 8·3
Well differentiated not functioning endocrine 
carcinoma of pancreas and digestive system
67·7 72·6 4·9 1·5 to 8·4
Soft tissue sarcoma of limbs 63·9 68·4 4·4 1·0 to 7·9
Adenocarcinoma with variants of oesophagus 9·9 13·8 3·9 2·6 to 5·1
Squamous cell carcinoma with variants of oral cavity 46·1 49·7 3·7 1·7 to 5·6
Squamous cell carcinoma with variants of hypopharynx 22·2 25·6 3·4 0·5 to 6·3
Other myeloproliferative neoplasms 70·8 74·0 3·2 0·6 to 5·9
Squamous cell carcinoma with variants of cervix uteri 65·1 68·1 3·0 1·6 to 4·5
Large cell carcinoma of lung 10·9 13·6 2·7 1·6 to 3·9
Adenocarcinoma with variants of extrahepatic biliary 
tract
16·2 18·7 2·6 0·2 to 5·0
Squamous cell carcinoma with variants of oesophagus 9·5 12·0 2·5 1·3 to 3·7
Hepatocellular carcinoma of liver and intrahepatic 
biliary tract
11·0 13·0 2·0 0·5 to 3·5
Other myelodysplastic syndrome 33·8 30·2 –3·5 –6·3 to –0·8
Data are rare cancers lying outside the 3 standard-errors confidence bounds in figure 2.
Table 3: Age-standardised 5-year relative survival in 1999–2001 and 2005–07
Figure 3: Mean admission volume by country and cancers ranked by pooled 
incidence level 
Data are for pooled countries, Belgium, Bulgaria, and Finland. 
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can be drawn from this seldom used source of information. 
However, several important limitations should be 
recognised. Seven cancer registries cannot be considered 
as statistically representative of the whole European 
population. Bulgaria, Finland, and Navarra only provided 
information about, at most, three treatments: the first 
surgical, systemic, and radiotherapy treatments. However, 
we estimated from the data of the other cancer registries 
that this problem only relates to about 1% of all patients.
The mean admission volume estimates, based on 
individual patient data and blind administrative coding 
of hospitals, will depend on how cancer services were 
organised and coded. We cannot know if, for some rare 
cancers and in some countries, hospitals were linked in 
organised networks during the study period, thus 
overcoming an apparent dispersion of treating structures. 
For example, patients with localised sarcomas or head 
and neck cancers were frequently treated by small or 
peripheral hospitals.23 If several hospitals provided 
different services but acted cooperatively as a single 
specialist centre, their estimated volume will depend on 
whether they were identified as single or separate units. 
Our data do not allow detailed identification of protocols 
used in the considered hospitals. Hospital volume can 
therefore be considered as only a partial quality indicator, 
mainly pointing to level of experience in protocol 
application and general management of patients with 
rare cancer.
To address the volume–survival assocation is beyond the 
scope of this paper, but centralisation of care has been 
suggested to improve outcomes for rare cancers.24 This is 
particularly true when optimal treatment requires 
complex surgery or high­technology radiotherapy 
equipment. Diagnosis and treatment in reference centres 
are expected to be more accurate because they benefit 
from large numbers of cases, which are often discussed in 
a multidisciplinary setting involving expert professionals. 
Often centralised sites are connected to research centres 
participating in international debates and research. 
Disadvantages of centralisation are the need for patients 
to locate to the centralised site, and the risk of a longer 
waiting list, with consequent discomfort and possible 
negative effects on outcome.25 Sometimes centralisation 
was only moderately perceived by oncologists as a solution 
to be endorsed for patients with rare cancers.26
For many of the solid rare cancers, centralisation did 
not seem to have been completely achieved during the 
study period. However, most cases had been diagnosed 
more than 10 years ago when centralisation for patients 
with cancer did not necessarily have much priority. 
Centralisation seemed to be more widely implemented 
for rare cancers requiring highly specific technologies 
(particularly radiotherapy and nuclear medicine) and for 
those with long­established evidence­based guidelines 
for diagnosis and treatment. This was the case for many 
paediatric tumours, uveal melanoma, anal canal cancers, 
adrenal cortex cancers and, for specific surgical expertise, 
in CNS cancers and bone sarcomas.
The degree of centralisation varied across Europe, and 
to a large extent was affected by the population size. 
In countries with a small population it is easier to 
concentrate patients in a single hospital or few hospitals. 
High admission volumes are more likely to be achieved 
in reference centres in larger­population countries.
The results of this part of the study were discussed in 
the participating countries at dedicated meetings attended 
by public health planners, oncologists, surgeons, repre­
sentatives of Ministries of Health, and patient 
associations. Although the general pattern of dispersion 
was recognised, almost all the countries were working at 
different levels to implement centralisation, or network­
based organisations for treatment, or both, while still 
following country­specific priorities.27
In Belgium, where all patients with cancer can be 
treated in any hospital with an oncology care programme, 
the level of centralisation was low. A plan is now under 
way for the development of hospital networks between 
centres of expertise and other oncology care services and 
programmes. Centralisation was already happening 
while we did this study in the Netherlands, mostly for 
surgical treatment. This was reflected in the high 
admission volumes in this country for many rare cancers 
(see appendix p 3).
In Bulgaria, patients with rare cancers were operated 
in all hospitals with surgical departments, whereas 
radiotherapy was concentrated in 17 centres and systemic 
therapy in 14 oncological hospitals. A problem was the 
quality of diagnosis, mainly due to inadequate facilities to 
diagnose many complex rare cancers. The definition of 
national and international pathways for second opinions 
from expert pathologists was deemed important by 
participants, for improving quality of rare cancer 
diagnoses. With this in mind, the European Reference 
Networks should offer a good opportunity to improve 
pathologist training through dedicated training schemes 
and fellowships across Europe. Cancer registration 
remains vital for monitoring progress in rare cancer 
diagnosis and treatment for these patients.
In Finland, more than 60% of patients with rare cancer 
were treated in five university hospitals. Centralisation in 
single national structures was only observed for uveal 
melanoma and retinoblastoma. Further centralisation for 
other rare cancers is impeded by the spread of the 
population over large areas and by administrative 
constraints on regional health authorities for referring 
patients with cancer to the closest university hospital.
Irish public health authorities, during the period 
covered by the study, identified centres to treat rare or 
particularly complex cancers. However, patients were not 
always correctly referred to them. This highlights the 
Figure 4: Mean admission volume by country and cancers ranked by pooled 
incidence level 
Data are for Ireland, The Netherlands, Slovenia, and Navarra.
Articles
1038 www.thelancet.com/oncology   Vol 18   August 2017
need for strong political commitment to ensure 
centralisation, to make sure all patients with rare cancer 
receive the highest quality of care.
Cancer care was highly centralised in Slovenia. 
Additionally, the major hospitals were organised on a 
task­specific basis: radiotherapy was only provided by the 
National Cancer Center, whereas surgical treatment was 
more often done in two other major hospitals. Reducing 
delays in diagnosis and treatment was recognised in 
Slovenia as one of the major challenges to improve rare 
cancer outcomes.
Navarra is a relatively small region of Spain, a country 
with a highly regionalised health organisation. No hospital 
with national recruitment for rare cancers was operating in 
Navarra, and 98% of resident patients with rare cancer 
were treated locally, the majority in the two largest regional 
hospitals. However, the admission volumes of Navarra 
hospitals were much lower than in all the other participating 
countries, even considering some underestimation due to 
unregistered patients coming from outside the region. This 
suggests some disadvantages in organising rare cancer 
treatment on a regional or local basis.
To conclude, to our knowledge, this is the largest study 
that estimates the burden of rare cancer for Europe, 
including trends in incidence and survival rates. This 
study also provides indicators of rare cancer treatment 
management. In seven European countries we observed, 
with few exceptions, a low level of centralisation of 
treatment for rare cancers. We recognise the importance 
of population­based cancer registries in descriptive 
studies like this, to ensure surveillance. However, the 
quality of the data needs to be improved when 
morphology, hospital, and treatment definitions are 
considered. To this aim, we suggest the use of specific 
Belgium (10·5*) Bulgaria (7·7*) Finland (5·3*) Ireland (4·2*) Netherlands (16·3*) Slovenia (2·0*) Navarra (0·6*)
Cases H75 Treat Cases H75 Treat Cases H75 Treat Cases H75 Treat Cases H75 Treat Cases H75 Treat Cases H75 Treat
Head and neck 2098 29 105·6 1180 10 145·1 439 6 82·2 368 7 63·0 2439 12 201·4 395 2 266·1 125 2 76·6
Epithelial ovary 760 50 19·5 627 16 52·3 370 10 44·5 261 15 21·0 1118 47 30·2 158 3 82·0 38 1 45·5
Oesophagus 689 31 29·3 77 14 5·2 163 8 21·6 289 9 37·1 1422 31 42·0 49 2 32·9 24 2 15·7
CNS 623 20 48·4 412 13 41·7 57 4 19·1 229 3 106·3 912 14 84·0 97 2 78·7 47 2 32·0
Soft tissue sarcoma 500 35 16·6 372 21 18·4 165 7 25·6 157 17 10·6 802 33 26·4 81 2 47·4 32 2 17·4
Thyroid 576 34 14·2 220 12 20·4 286 12 22·8 98 11 9·6 418 31 17·1 109 1 260·3 43 2 36·8
Testis 244 40 8·4 180 19 12·4 101 9 14·3 144 12 15·6 609 42 18·4 93 3 48·8 10 3 4·4
Biliary tract 214 44 4·9 183 23 6·5 147 13 11·3 122 14 7·7 582 38 12·2 47 3 13·2 43 2 19·7
Gastroenteric-pancreatic 
neuroendocrine tumour
287 46 5·6 30 21 1·3 148 13 9·3 61 20 2·7 355 44 6·9 22 3 6·8 10 3 2·9
Liver 250 22 11·0 107 12 7·6 165 11 12·8 68 12 4·6 236 36 5·2 29 2 14·4 49 3 14·5
Urinary tract 292 48 6·7 67 17 4·1 48 12 3·9 24 10 2·3 419 46 7·7 30 3 8·9 19 3 8·2
Mesothelioma 184 25 8·7 34 10 3·7 64 9 6·8 25 11 2·0 481 43 9·8 21 1 22·3 9 2 4·6
Vagina 172 35 5·8 120 9 14·0 70 5 14·8 40 9 4·7 296 14 21·8 42 2 21·9 8 2 4·7
Bone sarcoma 81 10 10·2 55 13 4·6 28 3 9·6 30 7 5·2 195 5 43·3 15 2 10·4 3 2 2·4
Anal canal 95 27 5·3 39 12 4·1 24 7 4·6 30 9 4·4 135 22 7·2 15 1 23·6 4 2 3·6
Melanoma of uvea 43 2 21·9 17 7 2·7 6 1 5·5 29 4 5·7 156 2 80·2 13 1 11·9 3 3 0·8
Penis 63 43 1·4 39 17 2·4 21 10 2·1 20 15 1·2 109 26 3·7 9 4 2·0 4 3 1·2
Small intestine 62 37 1·9 15 13 1·1 26 13 2·1 27 20 1·3 120 38 2·6 5 4 1·3 2 2 1·0
Neuroendocrine 
carcinoma of skin
46 32 1·9 1 3 0·4 0 15 18 0·8 77 37 2·3 4 4 1·1 0
Non-epithelial ovary 20 19 1·3 43 17 3·2 8 9 1·1 8 15 0·6 32 24 1·4 4 3 1·7 1 3 0·3
Endocrine carcinoma of 
thyroid
31 22 1·4 10 9 1·2 8 8 1·2 5 10 0·5 32 13 2·7 5 1 10·3 1 1 1·7
Thymus 22 20 1·4 7 8 1·3 4 5 1·1 5 5 1·3 36 15 2·8 3 2 2·1 2 2 1·3
Nephroblastoma 18 4 7·4 6 3 2·8 8 3 4·7 7 1 13·4 30 4 16·9 3 1 4·8 0 1 0·3
Melanoma of mucosa 14 24 0·8 2 5 0·8 10 7 1·7 6 11 0·6 34 13 3·0 4 3 1·5 1 2 0·3
Adrenal cortex 13 14 1·1 13 10 1·3 6 7 0·9 5 11 0·4 25 15 1·5 3 2 1·4 1 2 0·4
Embryonal CNS 21 9 4·2 14 9 2·5 6 3 3·1 9 3 6·3 0 2 4·2 2 1 5·2
Neuroblastoma 15 4 5·7 8 5 1·7 1 1 2·1 7 2 5·4 12 4 6·2 1 2 1·3 1 1 1·8
Retinoblastoma 10 1 14·0 3 5 0·5 3 2 1·5 3 2 1·8 22 1 30·7 1 1 1·1 1 2 0·5
Trachea 10 18 0·9 5 4 1·1 4 5 0·9 2 4 0·4 11 11 1·1 3 1 3·8 1 1 0·5
*Population in millions. Number of hospitals providing 75% of treatments (H75), mean annual number of treatments (treat) provided by H75 hospitals, by country and cancer group.
Table 4: Annual number of cases of rare tumours by country
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data quality indicators, the planning of periodic sample­
based quality studies and, above all, a wider use of these 
variables in population­based studies, with related 
sensitivity analysis. Furthermore, the international 
classification for cancer have to rapidly include the new 
entities on the basis of molecular and genomic 
categorisation. Genomic categorisation is a necessary 
condition for updating a new rare cancers list.
The European Network of Cancer Registries (ENCR) 
should work to boost these quality improvements and 
make wider use of the data on rare cancers. The Joint 
Action of Rare Cancers28 and the European Network for 
Rare Diseases will profit from these data, which are also 
useful for national and European policies to improve 
care for patients with rare cancer. The RARECAREnet 
project website includes a search tool with data for all the 
countries that contributed data.3
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